Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
This transaction fundamentally strengthens Scinai's CDMO platform
Iberdomide has the potential to be the first approved CELMoD agent
Over a two-decade career, Dr. Berman has worked on more than a dozen clinical-stage immunotherapies, including senior leadership roles in developing four oncology biologics
LOTTE Biologics will provide advanced manufacturing services for monoclonal antibody intermediates and their conjugates
CHOMax integrates cell line development, process development, analytics, and GMP manufacturing under robust quality processes
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Currently approved for patients eight and older, Tzield could now be used to delay the onset of stage 3 type 1 diabetes (T1D) in children diagnosed with stage 2 T1D
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Subscribe To Our Newsletter & Stay Updated
